Diagnostic value of the Epstein-Barr virus serological markers in patients with nasopharyngeal carcinoma in cases of undetectable primary tumor location

Cover Page


Cite item

Full Text

Abstract

The goal of this work was to describe a method for diagnosis of the non-keratinizing nasopharyngeal carcinoma (nNPC) in cases of the undetectable primary tumor location. The method is based on evaluation of IgG and IgA antibody levels to the capsid (VCA) and early antigens (EA) of the Epstein-Barr virus (EBV). The diagnosis of nNPC is established by a so-called decision rule. The latter was created by mathematical processing of the method of multifactor analysis of the results of anti-EBV antibody testing of 72 patients with clinically and morphologically confirmed nNPC and 72 patients with other head and neck benign tumors (OHNT) not associated with EBV, which were tested as a control group. The diagnostic value of the decision rule which was tested in the group of 77 patients with confirmed nNPC and 231 patients of a control group was high. The numbers of false negative and false positive cases were equal to 5.2% (4/77) and 6.5% (17/231), respectively. Among 32 patients with undetectable primary tumors the decision rule was able to identify 11 cases of nNPC. This diagnosis later was confirmed by morphological and instrumental methods of study. Only in two cases, false negative result was obtained (2/32; 6.3%) indicating that the serological diagnostics of nNPC with the decision rule is highly specific but not exact. Thus, the data obtained allowed us to conclude that the serological testing of EBV specific antibody evaluated by the decision rule can be recommended as an important test supplementing the standard methods of pdNPC diagnostics including cases with undetected primary tumor location.

About the authors

V. E. Gurtsevitch

FSBI «N.N. Blokhin Russian Cancer Research Center»

Author for correspondence.
Email: gurvlad532@yahoo.com
Russian Federation

N. B. Senyuta

FSBI «N.N. Blokhin Russian Cancer Research Center»

Email: noemail@neicon.ru
Russian Federation

M. V. Lomaya

FSBI «N.N. Blokhin Russian Cancer Research Center»

Email: noemail@neicon.ru
Russian Federation

A. V. Ignatova

FSBI «N.N. Blokhin Russian Cancer Research Center»

Email: noemail@neicon.ru
Russian Federation

T. E. Dushenkina

FSBI «N.N. Blokhin Russian Cancer Research Center»

Email: noemail@neicon.ru
Russian Federation

I. A. Repkina

FSBI «N.N. Blokhin Russian Cancer Research Center»

Email: noemail@neicon.ru
Russian Federation

A. I. Pavlovskaya

FSBI «N.N. Blokhin Russian Cancer Research Center»

Email: noemail@neicon.ru
Russian Federation

A. M. Mudunov

FSBI «N.N. Blokhin Russian Cancer Research Center»

Email: noemail@neicon.ru
Russian Federation

References

  1. Henle G., Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int. J. Cancer. 1976; 17: 1-7.
  2. Ho H.C., Ng M.H., Kwan H.C. Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. Br. J. Cancer. 1978; 37: 356-62.
  3. Ho H.C., Kwan H.C., Wu P., Chan S.K., Ng M.H., Saw D. Epstein-Barr antibodies in suspected nasopharyngeal carcinoma. Lancet. 1978; 2(8099): 1094-5.
  4. Ho H.C., Kwan H.C., Ng M.H., de The G. Serum IgA antibodies to Epstein-Barr virus capsid antigen preceding symptoms of nasopharyngeal carcinoma. Lancet. 1978; 1(8061): 436.
  5. Yi Z., Yuxi L., Chunren L., Sanwen C., Jihneng W., Jisong Z. et al. Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. Intervirology. 1980; 13(3): 162-8.
  6. Zeng Y., Pi G.H., Zhao W.P. Detection of EB virus nuclear antigen (EBNA) by anticomplement immunoenzymatic method. Zhongguo Yi. Xue. Ke. Xue.Yuan Xue.Bao. 1980; 2(2): 134-5.
  7. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 2001; 94(2): 153-6.
  8. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55(2): 74-108.
  9. Давыдов М.И. Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ. Вестник Российского онкологического научного центра имени Н.Н. Блохина РАМН. 2008; 19 (2 приложение 1).
  10. Barnes L., Eveson J.W., Reichart P., Sidransky D., eds. Pathology and Genetics Head and Neck Tumors. Lyon: IARC Press; 2005.
  11. Marks J.E., Phillips J.L., Menck H.R. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer. 1998; 83(3): 582-8.
  12. Лидовский В.В. Теория информации. Учебное пособие. М.; Компания «Спутник+»; 2004.
  13. Ho H.C., Ng M.H., Kwan H.C., Chau J.C. Epstein-Barr-virusspecific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br. J. Cancer. 1976; 34: 655-60.
  14. Pearson G.R. Epstein-Barr virus and nasopharyngeal carcinoma. J. Cell Biochem. Suppl. 1993; 17F: 150-4.
  15. Ringborg U., Henle W., Henle G., Ingimarsson S., Klein G., Silfversward C. et al. Epstein-Barr virus-specific serodiagnostic tests in carcinomas of the head and neck. Cancer. 1983; 52: 1237-43.
  16. Comess M.S., Beahrs O.H., Dockerty M.B. Cervical metastasis from occult carcinoma. Surg. Gynecol. Obstet. 1957; 104: 607-17.
  17. Белоусова Н.В., Михайловский А.А., Алексеева Т.Р., Шатская В.А. Эндоскопическая диагностика множественного первичного рака верхних дыхательных путей. Вестник оторинолярингологии. 1996; (2): 33-5.
  18. Белоусова Н.В., Поддубный Б.К., Унгиадзе Г.В., Кондратьева Т.Т., Азхипов В.В., Пробатова Н.А. и др. Современная диагностика рака носоглотки. Современная онкология. 2000; 2(3): 78-82.
  19. Li S., Deng Y., Li X., Chen Q.P., Liao X.C., Qin X. Diagnostic value of Epstein-Barr virus capsid antigen-IgA in nasopharyngeal carcinoma: a meta-analysis. Chin. Med. J. (Engl.). 2010; 123: 1201-5.
  20. Ling W., Cao S.M., Huang Q.H., Li Y.H., Deng M.Q. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong. Ai. Zheng. 2009; 28(1): 57-9.
  21. Luo Y.L., Ou G.P., Chi P.D., Liang Y.N., Liu Y.H., Huang M.Y. Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma. Ai. Zheng. 2009; 28(1): 76-8.
  22. Song C., Yang S. A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of Nasopharyngeal Carcinoma. Pak. J. Med. Sci. 2013; 29: 885-90.
  23. Sidransky D. Emerging molecular markers of cancer. Nat. Rev. Cancer. 2002; 2: 210-9.
  24. Skvortsova T.E., Rykova E.Y., Tamkovich S.N., Bryzgunova O.E., Starikov A.V., Kuznetsova N.P. et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br. J. Cancer. 2006; 94: 1492-5.
  25. Lichtenstein A.V., Melkonyan H.S., Tomei L.D., Umansky S.R. Circulating nucleic acids and apoptosis. Ann. N.Y. Acad. Sci. 2001; 945: 239-49.
  26. Lo Y.M., Chan L.Y., Chan A.T. Leung S.F., Lo K.W., Zhang J. et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999; 59: 5452-5.
  27. Hou X., Zhao C., Guo Y., Han F., Lu L.X., Wu S.X. et al. Different Clinical Significance of Pre- and Post-treatment Plasma Epstein-Barr Virus DNA Load in Nasopharyngeal Carcinoma Treated with Radiotherapy. Clin. Oncol. (R.Coll.Radiol). 2011; 23(2): 128-33.
  28. Leung S.F., Chan K.C., Ma B.B., Hui E.P., Mo F., Chow K.C. et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann. Oncol. 2014; 25: 1204-8.
  29. Wang W.Y., Twu C.W., Chen H.H. Jan J.S., Jiang R.S., Chao J.Y. et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin. Cancer. Res. 2010; 16: 1016-24.
  30. Twu C.W., Wang W.Y., Liang W.M. Jan J.S., Jiang R.S., Chao J. et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2007; 67: 130-7.
  31. Shao J.Y., Zhang Y., Li Y.H. Gao H.Y., Feng H.X., Wu Q.L. et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res. 2004; 24: 4059-66.
  32. Гурцевич В.Э., Сенюта Н.Б., Кондратова В.Н., Гончарова Е.В., Игнатова А.В., Ломая М.В. и др. Диагностическая значимость уровней ДНК и антител к капсидному антигену вируса Эпштейна-Барр в плазме крови больных раком носоглотки в неэндемичном регионе. Успехи молекулярной онкологии. 2015; 2(2): 56-67.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Gurtsevitch V.E., Senyuta N.B., Lomaya M.V., Ignatova A.V., Dushenkina T.E., Repkina I.A., Pavlovskaya A.I., Mudunov A.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies